Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Japan Pharma Market Forecast to Decline through FY2025: IQVIA
June 25, 2021
- BAN2401 Gets FDA’s Breakthrough Therapy Tag: Eisai/Biogen
June 25, 2021
- Boehringer, Japan Cancer Foundation Join Hands for Oncology Research
June 24, 2021
- Shionogi President Earns 242 Million Yen in FY2020
June 24, 2021
- Daiichi Sankyo Chief Takes Home 170 Million Yen in FY2020: Securities Report
June 23, 2021
- Opdivo Expands Label for Combo Use with Avastin/Chemo in NSCLC
June 23, 2021
- Roche Diagnostics’ ALK CDx Ventana Approved for Alunbrig
June 23, 2021
- MSD Tops Foreign Pharma List in Japan in FY2020, but Big Players in a Melee
June 23, 2021
- FoundationOne OK’ed as a CDx for Opdivo/Keytruda’s MSI-High Use: Chugai
June 23, 2021
- Mochida Seeks Japan Approval of Once-Daily Epadel
June 23, 2021
- Nichi-Iko Halts Supplies of Some Edirol Generic Products, Re-Supply Expected for September
June 22, 2021
- Yoshindo Announces Shipment Curbs for Cymbalta Generics, 6 Other APIs
June 22, 2021
- Otsuka Group Takes the Lead to Launch Workplace Vaccination as Industry Peers Set to Follow
June 22, 2021
- NanoCarrier’s Angiosarcoma Med Bags US FDA’s Fast Track Designation
June 22, 2021
- Yoshindo’s Cymbalta Generics Out, but Supply Restrictions in Place: Sources
June 21, 2021
- Astellas CEO Earns 488 Million Yen in FY2020: Securities Filing
June 21, 2021
- Global Brands Clinch Targeted Sales despite COVID-19, Drive Japan Makers in FY2020
June 21, 2021
- Eisai Forms Strategic Alliance with BMS for Its First ADC
June 21, 2021
- Astellas to Write Off 21.5 Billion Yen as Peanut Allergy Vaccine Fails
June 18, 2021
- Merck’s COVID-19 Drug Candidate Enters PIII in Japan
June 18, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…